Reposted by Christos Kallis
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif., October 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva...
finance.yahoo.com
October 20, 2025 at 11:14 AM
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
Reposted by Christos Kallis
The @kdigo.org IgA guidelines published www.kidney-international.org/article/S008...
We discussed them with Jon Barratt here: youtu.be/OChs5BcTEGE?... on #NephGR
We discussed them with Jon Barratt here: youtu.be/OChs5BcTEGE?... on #NephGR
KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those
of the authors and do not...
www.kidney-international.org
September 18, 2025 at 4:20 PM
The @kdigo.org IgA guidelines published www.kidney-international.org/article/S008...
We discussed them with Jon Barratt here: youtu.be/OChs5BcTEGE?... on #NephGR
We discussed them with Jon Barratt here: youtu.be/OChs5BcTEGE?... on #NephGR
Reposted by Christos Kallis
The era of ASIs is slowly dawning
www.nejm.org/doi/full/10....
(Yeah spironolactone is just as good and cheaper)
Disclosure: we recruited patients for this one
www.nejm.org/doi/full/10....
(Yeah spironolactone is just as good and cheaper)
Disclosure: we recruited patients for this one
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension | NEJM
Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension.
In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated
systolic blood pr...
www.nejm.org
August 30, 2025 at 2:39 PM
The era of ASIs is slowly dawning
www.nejm.org/doi/full/10....
(Yeah spironolactone is just as good and cheaper)
Disclosure: we recruited patients for this one
www.nejm.org/doi/full/10....
(Yeah spironolactone is just as good and cheaper)
Disclosure: we recruited patients for this one
Reposted by Christos Kallis
#WeekendReads from #EditorsChoice
Can you have normal looking adrenal glands with primary aldosteronism?
🔗 academic.oup.com/ajh/article/... 🔓
Can you have normal looking adrenal glands with primary aldosteronism?
🔗 academic.oup.com/ajh/article/... 🔓
Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism
AbstractBackground. Normal-appearing adrenal glands on cross-sectional imaging may still be the source of aldosterone production in primary aldosteronism (
academic.oup.com
August 31, 2025 at 12:30 PM
#WeekendReads from #EditorsChoice
Can you have normal looking adrenal glands with primary aldosteronism?
🔗 academic.oup.com/ajh/article/... 🔓
Can you have normal looking adrenal glands with primary aldosteronism?
🔗 academic.oup.com/ajh/article/... 🔓
Reposted by Christos Kallis
HiLo, HiLo it's off to work we go! ⛏️
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
High or Low Phosphate? Are we Missing the (P)oint? — NephJC
This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?
www.nephjc.com
August 5, 2025 at 1:08 AM
HiLo, HiLo it's off to work we go! ⛏️
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky
Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️
www.nephjc.com/news/hilo-tr...
Reposted by Christos Kallis
😎Check out the VA for HiLO by @sejalplakhani.bsky.social
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract
The HiLo Trial - Visual Abstract — NephJC
Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis? Check out this crisp VA by Dr Sejal Lakhani
www.nephjc.com
August 5, 2025 at 1:16 AM
😎Check out the VA for HiLO by @sejalplakhani.bsky.social
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract
Reposted by Christos Kallis
⚠️ The FDA has approved pegcetacoplan (Empaveli) for treating C3G and IC-MPGN. #kidneydisease #nephrology #nephsky #c3g www.docwirenews.com/post/fda-app...
FDA Approves Pegcetacoplan for C3G and IC-MPGN | Docwire News
The FDA approved pegcetacoplan for treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN in patients age 12 and older.
www.docwirenews.com
July 30, 2025 at 7:28 PM
⚠️ The FDA has approved pegcetacoplan (Empaveli) for treating C3G and IC-MPGN. #kidneydisease #nephrology #nephsky #c3g www.docwirenews.com/post/fda-app...
Reposted by Christos Kallis
just learned this & mind blown 🤯
CKD-EPI, MDRD etc give us GFR corrected for body surface area (ml/min/1.73m2)
BUT we're supposed to use the *absolute* GFR (ml/min) for drug dosing (eg KDIGO 2024 guidelines below; FDA agrees)
in obesity, the computer's ml/min/1.73m2 can be way too low #EMIMCC
CKD-EPI, MDRD etc give us GFR corrected for body surface area (ml/min/1.73m2)
BUT we're supposed to use the *absolute* GFR (ml/min) for drug dosing (eg KDIGO 2024 guidelines below; FDA agrees)
in obesity, the computer's ml/min/1.73m2 can be way too low #EMIMCC
April 14, 2025 at 3:01 PM
just learned this & mind blown 🤯
CKD-EPI, MDRD etc give us GFR corrected for body surface area (ml/min/1.73m2)
BUT we're supposed to use the *absolute* GFR (ml/min) for drug dosing (eg KDIGO 2024 guidelines below; FDA agrees)
in obesity, the computer's ml/min/1.73m2 can be way too low #EMIMCC
CKD-EPI, MDRD etc give us GFR corrected for body surface area (ml/min/1.73m2)
BUT we're supposed to use the *absolute* GFR (ml/min) for drug dosing (eg KDIGO 2024 guidelines below; FDA agrees)
in obesity, the computer's ml/min/1.73m2 can be way too low #EMIMCC
Reposted by Christos Kallis
Fascinating CKD data from ACC today. Some highlights from the data:
1.) Tirzepatide led to an *improvement* in eGFR at 52 weeks in all patients (by cystatin C), but only in patients with CKD (by eGFR-creatinine)
#NephSky
@hswapnil.medsky.social @kidneyboy.bsky.social
@nephjc.bsky.social
1.) Tirzepatide led to an *improvement* in eGFR at 52 weeks in all patients (by cystatin C), but only in patients with CKD (by eGFR-creatinine)
#NephSky
@hswapnil.medsky.social @kidneyboy.bsky.social
@nephjc.bsky.social
March 31, 2025 at 7:35 PM
Fascinating CKD data from ACC today. Some highlights from the data:
1.) Tirzepatide led to an *improvement* in eGFR at 52 weeks in all patients (by cystatin C), but only in patients with CKD (by eGFR-creatinine)
#NephSky
@hswapnil.medsky.social @kidneyboy.bsky.social
@nephjc.bsky.social
1.) Tirzepatide led to an *improvement* in eGFR at 52 weeks in all patients (by cystatin C), but only in patients with CKD (by eGFR-creatinine)
#NephSky
@hswapnil.medsky.social @kidneyboy.bsky.social
@nephjc.bsky.social
Reposted by Christos Kallis
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
March 29, 2025 at 3:34 PM
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
Reposted by Christos Kallis
💥 ADPKD = 6.9x ↑ risk of intracranial aneurysms (ICA)
🧠 KDIGO recommends ICA screening if:
📌 Personal hx of SAH
📌 Family hx of ICA, SAH, or unexplained sudden death
(1D) #NephJC
🧠 KDIGO recommends ICA screening if:
📌 Personal hx of SAH
📌 Family hx of ICA, SAH, or unexplained sudden death
(1D) #NephJC
March 26, 2025 at 1:41 AM
💥 ADPKD = 6.9x ↑ risk of intracranial aneurysms (ICA)
🧠 KDIGO recommends ICA screening if:
📌 Personal hx of SAH
📌 Family hx of ICA, SAH, or unexplained sudden death
(1D) #NephJC
🧠 KDIGO recommends ICA screening if:
📌 Personal hx of SAH
📌 Family hx of ICA, SAH, or unexplained sudden death
(1D) #NephJC
Reposted by Christos Kallis
#COL4A5-p.Gly624Asp is the Predominant #Variant in Europe Associated With a Mild #Alport Syndrome Phenotype
#VisualAbstract by @thana_susan
www.kireports.org/ar...
#VisualAbstract by @thana_susan
www.kireports.org/ar...
March 19, 2025 at 3:00 PM
#COL4A5-p.Gly624Asp is the Predominant #Variant in Europe Associated With a Mild #Alport Syndrome Phenotype
#VisualAbstract by @thana_susan
www.kireports.org/ar...
#VisualAbstract by @thana_susan
www.kireports.org/ar...
Reposted by Christos Kallis
Channel Your Enthusiasm, Chapter 17 of Burton Rose Clinical Physiology of Acid-Base and Electrolyte Disorders is out!
An hour and a half of "Introduction to Simple and Mixed Acid-Base Disorders!"
www.rosebook.club/episodes/202...
An hour and a half of "Introduction to Simple and Mixed Acid-Base Disorders!"
www.rosebook.club/episodes/202...
![[H+] = 24 x pCO2/[HCO3-]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:igrv2fjkj2zov2ab5bgdw4lm/bafkreihrbjjpdeyko42ltzzgnhb2eyzxeswxdtux3gz5bcoeozv6o6tequ@jpeg)
February 21, 2025 at 3:27 PM
Channel Your Enthusiasm, Chapter 17 of Burton Rose Clinical Physiology of Acid-Base and Electrolyte Disorders is out!
An hour and a half of "Introduction to Simple and Mixed Acid-Base Disorders!"
www.rosebook.club/episodes/202...
An hour and a half of "Introduction to Simple and Mixed Acid-Base Disorders!"
www.rosebook.club/episodes/202...
Reposted by Christos Kallis
🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial
Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes
#LupusNephritis #RheumSky #NephSky #MedSky #Lupus
Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes
#LupusNephritis #RheumSky #NephSky #MedSky #Lupus
February 12, 2025 at 10:16 PM
🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial
Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes
#LupusNephritis #RheumSky #NephSky #MedSky #Lupus
Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes
#LupusNephritis #RheumSky #NephSky #MedSky #Lupus
Reposted by Christos Kallis
I learned a lot about subclinical primary aldosteronism reading this piece from the unsinkable @brianrifkin.bsky.social 👇
www.nephjc.com/news/primary...
www.nephjc.com/news/primary...
Undercover Aldosterone — NephJC
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
www.nephjc.com
February 10, 2025 at 8:52 PM
I learned a lot about subclinical primary aldosteronism reading this piece from the unsinkable @brianrifkin.bsky.social 👇
www.nephjc.com/news/primary...
www.nephjc.com/news/primary...
Reposted by Christos Kallis
